Skip to main content
. 2011 May;31(5):433–440. doi: 10.1089/jir.2010.0054

FIG. 2.

FIG. 2.

Serum samples from melanoma patients were analyzed for TRAIL (A) and IL-1RA (B) expression at day 1 (pretreatment), day 8 and day 29 after IFNb-1a treatment. The level of TRAIL was determined using an ELISA and the level of IL-1RA was determined using the Luminex multi-analyte technology. Expression of both TRAIL and IL-1RA was significantly (*P < 0.001) increased after treatment. All patients received 22 × 106 IU/m2 on days 1–14 and 18 × 106 IU/m2 on days 15–29.